Atomoxetine

Also known as: (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine

Active ingredient description

Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
N06BA09
Atomoxetine
N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics
Discover more medicines within N06BA09

Medicines

$substanceName is the active ingredient of these drugs:

Drug
Countries
AGAKALIN

Germany

ATAMA

Hong Kong

ATAMAX

Spain

ATOFAB

Austria Poland

ATOMAID

United Kingdom

ATOMERRA

Australia

ATOMINEX

Estonia

ATOMOTERA

Hong Kong

ATOMOXE

Germany

ATTENTUS

South Africa

ATTEZE

South Africa

AUDALIS

Austria Netherlands

DEZAPREX

Spain

INIR

South Africa

KONATEN

Poland

NORBLOK

South Africa

PELLEGO

South Africa

STRADENT

South Africa

STRATEX

South Africa

STRATTERA

Australia Austria Canada Cyprus Ecuador

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
STRATTERA Capsule, hard
Summary of Product Characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 255.355 g/mol

External identifiers

CAS Substance: 83015-26-3
DrugBank Drug: DB00289
KEGG Drug: D07473
RxNorm Ingredient: 38400
SNOMED-CT Concept: 407037005
Atomoxetine (substance)
UNII Identifier: ASW034S0B8
ATOMOXETINE
 
Next: Usage >